TORONTO, April 21, 2021 /CNW/ – Aion Therapeutic Inc. (CSE: AION) (“ Aion Therapeutic” or the “Company“) announced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the “Aion Mushroom Preparations” or “Preparations“) showed high efficacy in killing HER2+ breast cancer cells, ER+/PR+ breast cancer cells, and triple-negative breast cancer…


Previous articleSilo Wellness Announces Five New Psychedelic Wellness Retreats in Jamaica
Next articleSilo Pharma (SILO) Announces Plans to Uplist to the NASDAQ